florbetapir f-18 · Avid Radiopharms Inc · NDA 202008

Amyvid

Earliest generic entry, as listed · earliest of 2 marketed strengths
30 Apr 2027

Blocked by patent: US 7687052, US 8506929.

Listed patents · 2 unexpired

PatentClaimsExpires
US 7687052drug substance, drug product, use U-4217 · sets the listed date30 Apr 2027
US 8506929drug substance, drug product, use U-4217 · sets the listed date30 Apr 2027

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • Enters 12-month window basis: patent · 202008-003Listed date 30 Apr 2027Detected 24 Oct 2026
  • Enters 12-month window basis: patent · 202008-002Listed date 30 Apr 2027Detected 24 Oct 2026
  • Enters 12-month window basis: patent · 202008-004Listed date 30 Apr 2027Detected 24 Oct 2026
  • Enters 12-month window basis: patent · 202008-001Listed date 30 Apr 2027Detected 24 Oct 2026

Products covered · 4

NDA · productFormStrengthListed expiry
202008 · 001 · RLD · discontinuedsolution, intravenous10ML (13.5-51mCi/ML)30 Apr 2027
202008 · 002 · RLD · discontinuedsolution, intravenous10-30ML (13.5-51mCi/ML)30 Apr 2027
202008 · 003 · RLDsolution, intravenous10-50ML (13.5-51mCi/ML)30 Apr 2027
202008 · 004 · RLDsolution, intravenous10-100ML (13.5-51mCi/ML)30 Apr 2027